Firdapse: first treatment for Lambert-Eaton myasthenic syndrome

Firdapse (amifampridine) is the first drug to be approved for the treatment of Lambert-Eaton myasthenic syndrome.

Amifampridine improves muscle strength and increases resting compound muscle action potential through blockade of voltage-dependent potassium channels, which results in increased intracellular calcium concentrations and leads ultimately to enhanced neuromuscular transmission.

Treatment is given on a daily basis in 3 or 4 divided doses and should be initiated under the supervision of a physician experienced in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Because of the rarity of the condition data on amifampridine are limited and the product information will therefore be reviewed annually by the European Medicines Agency.

View Firdapse drug record

Further information: BioMarin Europe

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases